EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial

Yasir Alayed, Darin Gopaul, Lucas C Mendez, Winkle Kwan, Stanley K Liu, William Chu, Chia-Lin Tseng, Patrick Cheung, Danny Vesprini, Hans Chung, Gerard Morton, Rohan Correa und 8 weitere

Clinical and Translational Radiation Oncology · 2027-01 · 62 · 101256

DOI: 10.1016/j.ctro.2026.101256 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Radiation Oncology, 2027-01. Verfasst von Yasir Alayed und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Given the complexity of SABR to the pelvis in prostate cancer (PCa), it was important to establish the safety and feasibility in a multicentric setting. We report the outcomes of a multicenter, phase II study of SABR with elective nodal irradiation (ENI) and an optional prostate focal boost.

Methods

Patients had unfavorable-intermediate or high-risk PCa. All patients received 5 fractions SABR weekly delivering 25Gy ENI and 40Gy to prostate simultaneously, with an optional 50Gy focal prostate boost. All patients had ADT. Primary endpoint was acute GI and GU adverse events (AE).

Results

76 patients were accrued at 4 hospitals with a median follow-up of 62.8 months. 63% of patients had high-risk PCa. 41% of patients had a focal boost. Acute grade ≥ 2 GI and GU AE was 4.1% and 18%. At 5 years, 2.9% and 4.3% of patients had grade 2 GI and GU AE, and no grade 3+ GI/GU AE was observed at the last follow-up. 5-year cumulative biochemical failure was 10.5%. The median PSA nadir was 0.2 ng/mL. 84% of patients recovered their testosterone level, with a median time of 14.3 months. 2.9%, 5.9% and 4.6% of patients had a large change in QOL (SD*2) in the EPIC urinary, bowel, and sexual domains.

Conclusions

5-fraction SABR to prostate and pelvis for unfavorable-risk PCa was safe and feasible in a multicentric setting with or without a focal boost. There were few significant AE, encouraging PSA kinetics and biochemical control. The results are currently being validated in randomized trials.

Schlagwörter

Stichwörter der Autor:innen

focal boostprostate cancerquality of lifestereotactic ablative radiotherapytoxicity

Autor:innen und Institutionen

  • Division of Radiation Oncology, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
  • Grand River Regional Cancer Center, Kitchener, ON, Canada.
  • London Health Sciences Centre, London, ON, Canada.
  • BC Cancer, Surrey, BC, Canada.
  • Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada.
  • Durham Regional Cancer Centre, Oshawa, ON, Canada.

Zitieren

APA

Alayed, Y., Gopaul, D., Mendez, L. C., Kwan, W., Liu, S. K., Chu, W., Tseng, C. L., Cheung, P., Vesprini, D., Chung, H., Morton, G., Correa, R., Musunuru, B., Davidson, M., Ravi, A., Deabreu, A., Mamedov, A., Poon, E., Zhang, L., & Loblaw, A. (2027). Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial. Clinical and Translational Radiation Oncology, 62, 101256. https://doi.org/10.1016/j.ctro.2026.101256

Vancouver

Alayed Y, Gopaul D, Mendez LC, Kwan W, Liu SK, Chu W, et al. Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial. Clinical and Translational Radiation Oncology. 2027;62:101256. doi:10.1016/j.ctro.2026.101256

BibTeX
@article{Alayed2027,
  author = {Alayed, Yasir and Gopaul, Darin and Mendez, Lucas C and Kwan, Winkle and Liu, Stanley K and Chu, William and Tseng, Chia-Lin and Cheung, Patrick and Vesprini, Danny and Chung, Hans and Morton, Gerard and Correa, Rohan and Musunuru, Bindu and Davidson, Melanie and Ravi, Ananth and Deabreu, Andrea and Mamedov, Alexander and Poon, Evan and Zhang, Liying and Loblaw, Andrew},
  title = {Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial},
  journal = {Clinical and Translational Radiation Oncology},
  year = {2027},
  volume = {62},
  pages = {101256},
  doi = {10.1016/j.ctro.2026.101256}
}
Kostenlos starten →